Skip to main content

Treatment Clinical Trials for Chronic Lymphocytic Leukemia (CLL)

Review the chronic lymphocytic leukemia (cll) treatment clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 51-75 of 109

A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Status: Active
Location: Stanford Cancer Institute Palo Alto, Palo Alto, California
Venetoclax and Ibrutinib or Acalabrutinib in Treating Patients with High-Risk Chronic Lymphocytic Leukemia
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic Leukemia
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Pirtobrutinib (LOXO-305) and Venetoclax for the Treatment of Patients with CLL or SLL Resistant to Covalent BTKi
Status: Active
Location: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Acalabrutinib in Combination with Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic Leukemia
Status: Active
Location: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Pneumococcal Pneumonia Vaccine Series (PCV20 and PPSV23) in Patients with Chronic Lymphocytic Leukemia Associated Immunodeficiency, PROTECT CLL Trial
Status: Active
Location: Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah
Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)
Status: Active
Location: Long Island Jewish Medical Center, New Hyde Park, New York
Niacinamide for the Treatment of Patients with Chronic Lymphocytic Leukemia with History of Non-melanoma Skin Cancer
Status: Active
Location: Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah
A Vaccine Booster (GEO-CM04S1 or Pfizer-BioNTech) for the Prevention of COVID-19 in Patients with Chronic Lymphocytic Leukemia
Status: Active
Location: City of Hope Comprehensive Cancer Center, Duarte, California
Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation from Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Status: Active
Location: 2 locations
Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype
Status: Active
Location: Roswell Park Cancer Institute, Buffalo, New York
Risk-ADAPTed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation
Status: Active
Location: UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California
Combination Pirtobrutinib, Venetoclax, and Obinutuzumab for the Treatment of Untreated Chronic Lymphocytic Leukemia or Untreated, Recurrent, or Refractory Richter Transformation
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia
Status: Active
Location: Dana-Farber - Harvard Cancer Center LAO, Boston, Massachusetts
Acalabrutinib in Combination with Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, The AVENUE-2 Trial
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Acalabrutinib and Venetoclax with or without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants with Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Donor Stem Cell Transplant with Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Donor Stem Cell Transplant in Treating Patients with Blood Cancer
Status: Active
Location: University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota
Chemotherapy with or without Total Body Irradiation before Stem Cell Transplant in Treating Patients with Hodgkin or Non-Hodgkin Lymphoma
Status: Active
Location: University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota
Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Chronic Lymphocytic Leukemia (CLL)
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Acalabrutinib Maintenance for the Treatment of Patients with Large B-cell Lymphoma
Status: Active
Location: 2 locations
131I-Apamistamab Followed by Axicabtagene Ciloleucel for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma, The IOMAB-ACT Trial
Status: Active
Location: UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas
Lenalidomide with Tafasitamab for the Treatment of Relapsed Central Nervous System Diffuse Large B-cell Lymphoma
Status: Active
Location: University of California San Francisco, San Francisco, California
Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland